National Biopharmaceutical Company FORT LLC – Russian national full-cycle biopharmaceutical company. Company directions are: researching, developing, manufacturing and marketing of innovative biological medicines.
In 2014, FORT successfully completed a project for the construction of its own complete cycle of research and production complex compliant to the international Good Manufacturing Practice. The factory is located in the Ryazan region on the territory of 16.5 hectares, the total area of ​​outstanding buildings is 39.8 thousand square meters.
The company meets all international license requirements for work with micro-organisms (even the dangerous ones) causing the infection. Plant for vaccine production, laboratory and warehouse and all modern infrastructural facilities to ensure full operation of the plant were launched .
The production capacity of the first stage is 40 million doses of seasonal influenza vaccines, or, if necessary, 120 million doses of pandemic influenza vaccines; 20 million doses of other anti-viral vaccines; 100 million doses of recombinant pharmaceutical proteins.

FORT increases its sales of influenza vaccine

In 2018, FORT, a biopharmaceutical company which is part of Marathon Group and Nacimbio (Rostec Corporation), doubled its yoy sales of Ultrex, an influenza vaccine.

Vnesheconombank restructures the debt of Ryazan-based FORT

Vnesheconombank allowed FORT, a pharmaceutical manufacturer based in Ryazan, to continue using its credit facility on the terms favorable for the company

Anton Katlinsky says that Russia cannot wait in a queue to get the vaccines

Anton Katlinsky, the Advisor to the CEO of Nacimbio and the President of FORT, a biopharmaceutical company, discussed with other experts the scenarios for provision of vaccines to the Russian market

Nacimbio presents its key projects and new R&D

Nacimbio, a pharmaceutical holding company of Rostec Corporation, takes part in PharmMedProm-2017 exhibition held during the Russian Health Care Week

Nacimbio will invest 2.2 billion rubles in vaccine manufacturing

The Governor of the Ryazan region and the President of FORT LLC have signed an agreement to extend the provision of state support

FORT increases the investments in its Russian biopharmaceutical plant

The meeting of the Investment Council of the Ryazan region reviewed the application of FORT LLC to modify the agreement with the government of the region

Transition to multicomponent preventive drugs is necessary

influenza vaccine
During the second BIOTECHMED conference, the representatives of Nacimbio participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar

Pharmaceutical manufacturing index jumps by 45.6% in Ryazan region

In H1 2017, the manufacturing index of medicinal products and materials used for medical purposes increased by 45.6% in the Ryazan region

Marathon Pharma buys a controlling stake in the Fort plant

Marathon Pharma Group signed an agreement to acquire a controlling stake in Fort LLC, a biopharmaceutical company that is a part of Nacimbio of Rostec Corporation.

Quadrivalent influenza vaccine will be available in Russia by 2019

Russian manufacturers of pharmaceuticals are ready to present a new quadrivalent influenza vaccine protecting against four different flu strains before the start of epidemic season in 2019. “It is ...

Students of the Ryazan Medical University will be able to undertake an internship at the FORT produc...

FORT - Student Tour
On 18-19th of January 2017, the fourth year students of the Faculty of Pharmacy and the leading teachers of the Department of pharmaceutical technology in the framework of a cooperation agreement with...